Format

Send to

Choose Destination
F1000Res. 2017 Feb 9;6:123. doi: 10.12688/f1000research.9736.1. eCollection 2017.

Serotonin receptors in depression: from A to B.

Author information

1
Division of Integrative Neuroscience, New York State Psychiatric Institute, and Department of Psychiatry, Columbia University, NY, USA.
2
Division of Integrative Neuroscience, New York State Psychiatric Institute, and Department of Psychiatry, Columbia University, NY, USA; Departments of Neuroscience and Pharmacology, Columbia University, NY, USA.

Abstract

The role of serotonin in major depressive disorder (MDD) is the focus of accumulating clinical and preclinical research. The results of these studies reflect the complexity of serotonin signaling through many receptors, in a large number of brain regions, and throughout the lifespan. The role of the serotonin transporter in MDD has been highlighted in gene by environment association studies as well as its role as a critical player in the mechanism of the most effective antidepressant treatments - selective serotonin reuptake inhibitors. While the majority of the 15 known receptors for serotonin have been implicated in depression or depressive-like behavior, the serotonin 1A (5-HT 1A) and 1B (5-HT 1B) receptors are among the most studied. Human brain imaging and genetic studies point to the involvement of 5-HT 1A and 5-HT 1B receptors in MDD and the response to antidepressant treatment. In rodents, the availability of tissue-specific and inducible knockout mouse lines has made possible the identification of the involvement of 5-HT 1A and 5-HT 1B receptors throughout development and in a cell-type specific manner. This, and other preclinical pharmacology work, shows that autoreceptor and heteroreceptor populations of these receptors have divergent roles in modulating depression-related behavior as well as responses to antidepressants and also have different functions during early postnatal development compared to during adulthood.

KEYWORDS:

5-HT1A; 5-HT1B; 5-HTT; MDD; antidepressant; major depressive disorder; selective serotonin reuptake inhibitors; serotonin; serotonin receptor

Conflict of interest statement

Competing interests: The authors declare that they have no competing interests.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central
Loading ...
Support Center